Precision Medicine Advances in Pediatric Sarcoma: NTRK-Targeted Therapy and Multimodal Care Transform Outcomes
核心洞察
Sarcomas account for at least 11% of all pediatric cancer diagnoses, affecting nearly 1,800 children in the United States each year, with more than 70 distinct subtypes complicating diagnosis and treatment.
The 2018 FDA approval of larotrectinib for NTRK (搜索) fusion-positive cancers, including rare pediatric sarcomas, delivered high response rates with fewer side effects than traditional chemotherapy.
Precision medicine now matches treatment to the genetic changes driving a child's cancer, exemplified by patients like Lakelynn, who experienced a remarkable response to larotrectinib.
Sarcomas represent a significant and complex challenge in pediatric oncology, accounting for at least 11% of all pediatric cancer diagnoses and affecting nearly 1,800 children in the United States each year. The word sarcoma (搜索) derives from the Greek words for "fleshy" and "tumor," reflecting the fact that these cancers arise in the body's connective tissues—including bone, muscle, cartilage, fat, tendons, ligaments, and other supportive tissues. Because connective tissue exists throughout the body, sarcomas can develop in many different places and behave in very different ways, making diagnosis and treatment especially complex.
A Diverse Group of More Than 70 Cancers
Pediatric sarcomas are not one disease, but a diverse group of more than 70 cancers. Some begin in bone, while others develop in muscle, fat, nerves, or other connective tissues. Each type has its own biology, meaning treatment approaches and outcomes can differ considerably. Examples include osteosarcoma (搜索), Ewing sarcoma (搜索), rhabdomyosarcoma (搜索), infantile fibrosarcoma, desmoplastic small round cell tumor, alveolar soft part sarcoma (搜索), desmoid tumors, inflammatory myofibroblastic tumor, NTRK (搜索)-rearranged spindle cell sarcoma, and synovial sarcoma.
Rhabdomyosarcoma (搜索), which develops from cells related to skeletal muscle, is among the more common of these rare cancers. According to University of Florida Health pediatric oncologist Joanne Lagmay, MD, about 350 to 500 children and adolescents are diagnosed with rhabdomyosarcoma each year in the United States, making up about 3% to 5% of childhood cancers. Dr. Lagmay, chief of the UF Division of Pediatric Hematology/Oncology and research leader of the sarcoma (搜索) Disease Site Group at the UF Health Cancer Institute (搜索), described rhabdomyosarcoma as an aggressive soft tissue cancer that develops from immature cells that normally form skeletal muscles and can occur throughout the body.
Metastasis Complicates Treatment and Lowers Survival
Some sarcomas become especially difficult to treat once they spread, or metastasize, to other parts of the body. Bone sarcomas such as osteosarcoma (搜索) and Ewing sarcoma (搜索) commonly spread to the lungs, where treatment becomes more challenging and survival rates are significantly lower than when the disease is localized.
The clinical course of relapsed disease underscores the stakes involved. Sawyer Bozeman, diagnosed with anaplastic rhabdomyosarcoma (搜索) in 2022, initially underwent six months of chemotherapy followed by 18 months of clear scans. However, in July 2024, the cancer returned. "The most difficult moment was learning that Sawyer's cancer had relapsed," Dr. Lagmay said. "It was unexpected and meant that he would need a much longer and more aggressive course of treatment involving chemotherapy, radiation and major surgery."
Precision Medicine Is Changing What Is Possible
One of the most exciting advances in pediatric sarcoma (搜索) research is precision medicine—matching treatment to the genetic changes that drive a child's cancer. In 2018, the FDA approved larotrectinib for cancers with a specific genetic change called an NTRK (搜索) fusion, including certain rare pediatric sarcomas. This milestone, made possible in part through research supported by Alex's Lemonade Stand Foundation (搜索) (ALSF), provided a new targeted therapy with high response rates and fewer side effects than traditional chemotherapy for many eligible patients.
Lakelynn was diagnosed with a rare, inoperable sarcoma (搜索) at age 3. She was treated with larotrectinib and experienced a remarkable response. Today, Lakelynn is 12 years old and thriving. Her story reflects what is possible when scientific discoveries become new treatment options for children.
Multimodal Treatment Aims for Long-Term Remission
For aggressive and relapsed disease, treatment intensification across multiple modalities is critical. After Sawyer Bozeman's relapse, his care team pursued an intensive combination of therapies. "We intensified his treatment with radiation, surgery and additional chemotherapy because our goal was not simply a response," Dr. Lagmay said. "It was to maximize his chance of achieving a long-term remission and, ultimately, a cure."
After about three months of aggressive chemotherapy, scans showed Sawyer's tumors had significantly shrunk. Following his response, Sawyer was eligible for additional surgery. His family traveled to Minnesota, where surgeons removed tissue from areas where cancer had previously been found and treated his abdomen with heated chemotherapy, known as HIPEC. HIPEC, or hyperthermic intraperitoneal chemotherapy, is a treatment in which heated chemotherapy is circulated directly through the abdomen after surgery to target cancer cells that may remain. Sawyer continued chemotherapy and later underwent a month of radiation treatment at the UF Health Proton Therapy Institute in Jacksonville.
Sawyer's treatment required collaboration among pediatric specialists in oncology, urology and surgery, as well as radiation oncology. Pediatric oncology coordinated his treatment and chemotherapy, while the other teams managed surgery and radiation as his needs changed.
Research Is Driving the Next Breakthrough
Every advancement in childhood cancer treatment begins with research. Alex's Lemonade Stand Foundation (搜索) has funded more than 280 sarcoma (搜索)-focused research grants, helping scientists better understand these rare cancers and develop more effective treatments.
Taylor was 11 years old when pain in her arm—initially thought to be a sports injury—was diagnosed as osteosarcoma (搜索). After conventional treatments failed, she enrolled in a clinical trial led by an ALSF-funded researcher. That trial gave Taylor another chance. Today, she is a nurse, a wife, and the mother of two children—living proof of the life-changing impact that research can have for children with cancer.
Every child diagnosed with sarcoma (搜索) has a different journey. Some become long-term survivors. Some continue to live with the lasting effects of treatment. And some remind us why there is still so much work to do. Research is helping clinicians better understand these rare cancers, develop more effective therapies, and bring hope to families facing a diagnosis today.